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Summary The monoclonal anti-CEA antibody, A5B7, has previously been administered to patients for
radioimmunotherapy (RIT). Long circulation time and the formation of an immune response have limited
therapeutic success in the clinic. Antibody fragments can be used to reduce the in vivo circulation time, but the
best combination of fragment and radioisotope to use for therapy is far from clear. In this study we have
compared the biodistribution of A5B7 IgG and F(ab')2 with chemically cross-linked divalent (DFM) and
trivalent (TFM) A5B7 Fab' fragments in nude mice bearing human colorectal tumour xenografts. The cross-
linkers were designed to allow site-specific labelling using yttrium 90 (90Y), a high-energy f-emitter. We have
also compared the above antibody forms conjugated to both 13'I and 9'Y. Both DFM and TFM were fully
immunoreactive and remained intact after radiolabelling and incubation in serum at 37°C for 24 h.
Biodistribution results showed similar tumour uptake levels and an identical blood clearance pattern for F(ab')2
and DFM with high tumour-blood ratios generated in each case. However, unacceptably high kidney
accumulation for both F(ab')2 and DFM and elevated splenic uptake of DFM labelled with 9'Y was observed.
Kinetic analysis of antigen binding revealed that DFM had the fastest association rate (kass = 1.6 x 105 Ms-1)
of the antibody forms, perhaps owing to increased flexibility of the cross-linker. This advantage implies that
DFM may be more suitable than F(ab')2 radiolabelled with 13'I for RIT. TFM cleared from the blood
significantly faster than A5B7 IgG when labelled with both 13'I and 9'Y, producing an improved therapeutic
tumour-blood ratio. Kidney accumulation was not observed for [90Y]TFM, but a slightly higher splenic
uptake was observed that may indicate reticuloendothelial system (RES) uptake. Overall, tumour uptake was
higher for 90Y-labelled antibodies than for '3'I-labelled antibodies. Because of the faster clearance, it should be
possible to administer a higher total dose of 90Y-labelled TFM than IgG, which is attractive for RIT. Both
A5B7 DFM and TFM, therefore, show favourable properties compared with their parent antibody forms.
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The use of antibodies to deliver radiation selectively to
tumours for therapeutic and diagnostic purposes is now well
established (Waldmann, 1991; Jurcic and Scheinberg., 1994;
Larson et al., 1994). The murine A5B7 antibody raised
against carcinoembryonic antigen (CEA) has been used for
both imaging and therapy in nude mice bearing human
colorectal tumour xenografts (Pedley et al., 1993) and in
patients (Lane et al., 1994). However, results from clinical
trials using this antibody, and many other studies on the
treatment of solid tumours, have been disappointing,
considering the success in mice (Begent and Pedley, 1990;
Delaloye and Delaloye, 1995). In spite of this, some patient
responses to radioimmunotherapy (RIT) have been reported
(Begent and Pedley, 1990; Lane et al., 1994), suggesting that
improvements to current methodology may be clinically
beneficial.
There are a number of factors thought to influence
antibody localisation to the tumour, which may account for
the wide variation in tumour uptake levels between patients
(Boxer et al., 1992). These include heterogeneous expression
of antigen, variable levels of antibody achieved in the blood,
the presence of circulating antigen, tumour vascularisation
and the penetration of antibody into tumour tissue. In
addition, RIT is often limited by the toxicity of circulating
activity, particularly to the bone marrow. In attempts to
overcome these problems, several strategies have been
attempted to improve the delivery to tumours, while
removing circulating radiolabelled antibody more rapidly, in
order to reduce the dose to the bone marrow. These include
the use of specific clearing regimens either in vivo or ex vivo
(Begent et al., 1987; Norrgren et al., 1993), the use of two-
step targeting regimens (Goodwin et al., 1994) and the use of
antibody fragments.
F(ab')2 fragments have been widely investigated for RIT,
both in animal models and in the clinic (Lane et al., 1994). It
has been shown that, in some situations, F(ab') fragments
may be more suitable for RIT than intact IgG labelled with
131I (Buchegger et al., 1990; Yorke et al., 1991). However,
comparatively few studies have attempted to identify the
most suitable fragments for RIT with different isotopes.
Small antibody fragments such as Fv and single-chain Fv
(scFv) fragments showed improved penetration into tumour
tissue (Yokota et al., 1992). ScFv fragments also show
favourable tumour-blood ratios and are potentially excellent
reagents for tumour imaging (Chester et al., 1994). However,
the dose of antibody delivered to the tumour by these rapidly
cleared fragments is relatively low and further development is
required before a therapeutic tumour dose could be delivered.
We have been evaluating alternative reagents comprising
multivalent Fab's produced by chemical cross-linking.
Chemically cross-linked di-Fab (DFM) and tri-Fab (TFM)
have been prepared from the mouse-human chimeric Fab'
fragment of B72.3 (King et al., 1994) and an engineered
human form of the antibody (King et al., 1995). Biodistribu-
tion studies with these antibodies have revealed higher
tumour accumulation than seen with scFvs, although
clearance from the blood is still rapid. In addition, the
choice of antibody fragment for RIT may be different for
different isotopes. It is well known that the biodistribution of
antibody fragments labelled with radioiodine is very different
from those labelled with metallic radionuclides such as .'.In,
90Y, '77Lu, 67Cu and 99'Tc (Brown et al., 1987; Sharkey et al.,
1990; Schott et al., 1992). The purpose of this study was,
therefore, to determine which was the optimal form of the
antibody A5B7 for RIT with the isotopes 131I and 90Y.
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In particular, we have developed methods for the production
of murine versions of DFM and TFM of A5B7 to allow
biodistribution studies of the murine antibody fragments in
the nude mouse xenograft system. Although models of this
type have been shown to have many limitations, particularly
with regard to relative tumour size and accessibility, they
have been shown to generate tumour-normal tissue ratios in
mice similar to those observed in humans administered with
the same antibody (Begent and Pedley, 1990). The
biodistribution of the murine reagents produced here may
be more representative of the behaviour of engineered human
antibodies in patients than direct mouse studies with the
recombinant humanised reagents.
Material and methods
Preparation ofF(ab')2 fragments
ASB7, (IgG 1) was dialysed into 0.1 M sodium acetate, pH
5.5, containing 3 mM EDTA and concentrated by ultrafiltra-
tion using a pressurised stirred cell fitted with a YM10
membrane (Amicon) to 10 mg ml-'. Bromelain (5 mg)
(Sigma) was activated by incubation with freshly prepared
50 mM cysteine (4 ml) in the same buffer for 30 min at 37°C.
Activated bromelain was buffer exchanged on a Sephadex G-
25 prepacked PD-10 column (Pharmacia) and the concentra-
tion of enzyme determined by absorbance at 280 nm.
Digestion was performed by incubation of antibody
(approximately 100 mg) with enzyme at a ratio of 50:1
(w/w) with gentle mixing at 37°C. Digestion was periodically
monitored by high-performance liquid chromatography
(HPLC) gel filtration analysis on a Zorbax GF-250
analytical column (DuPont), at- a flow rate of 1 ml min-'
with a 0.2 M sodium phosphate, pH 7.0, mobile phase, and
was usually complete in 1 h. The reaction mix was adjusted
to pH 6.0 with 0.1 M sodium hydroxide and bromelain was
rapidly removed at 4°C by loading onto an SP-Sepharose
(Pharmacia) column (approximately 30 ml) equilibrated with
0.1 M sodium acetate, pH 6.0. F(ab')2 was eluted with 0.5 M
sodium chloride and further purified by gel filtration on a
2 m x 2.6 cm diameter Sephacryl S-200 (Pharmacia) column
equilibrated in 0.1 M sodium acetate/0.1 M potassium
chloride buffer, pH 6.0, containing 3 mM diethylenetriamine
penta-acetic acid (DTPA), at a flow rate of 0.3 ml min-'.
Cross-linking
Purified F(ab')2 was concentrated by amicon ultrafiltration to
approximately 5 mg ml-' and buffer exchanged to 0.1 M
sodium acetate, pH 8.0, containing 2 mm DTPA. F(ab')2
was partially reduced to form Fab' fragments to produce a
free hinge thiol for cross-linking, using 2-mercaptoethylamine
(Fluka) at a final concentration of 5 mM for 30 min at 37°C.
The reducing agent was then removed by desalting on a PD-
10 column, and the presence of free thiols was measured by
titration with 4',4'-dithiodipyridine (Sigma) and measurement
of the thiopyridine released at 324 nm. Cross-linking to DFM
was performed by incubating desalted reduced Fab' with 12-
N4-macrocycle containing dimaleimide linker CT52, for 2 h
at 37°C at a molar ratio of 2:1. TFM was prepared using
Fab' in the same way by cross-linking with a 12-N4-
macrocycle containing trimaleimide linker CT998, at a 3-
fold molar excess of Fab' -linker. Detailed synthesis and
chemical structure of the cross-linkers, CT52 and CT998, has
been previously described by King et al. (1994).
Preparation of antibodies for 90Y labelling was performed
under metal-free conditions. This was achieved by use of
Milli-Q SP deionised water (Millipore), high-quality reagent
buffers and metal-free containers. Purification of DFM and
TFM after cross-linking was achieved by HPLC gel filtration
using a Zorbax GF-250XL column run at a flow rate of
3 ml min-' in 0.2 M sodium phosphate, pH 7.0, containing
2 mM DTPA. To confirm purity, SDS-PAGE under non-
reducing conditions was performed. To check for the
presence of reoxidised F(ab')2 in the DFM, a small sample
of DFM was reduced as above and alkylated with excess N-
ethlymaleimide. HPLC analysis was used to calculate the
percentage of F(ab')2 in the sample relative to DFM.
Preparation ofIgG and F(ab')2 macrocycle conjugates
A5B7 IgG and F(ab')2 were dialysed into 0.1 M sodium
phosphate, pH 8.0, containing 2 mM DTPA and incubated
with a 10-fold molar excess of 2-iminothiolane hydrochloride
(Sigma) for 30 min at room temperature. Unreacted reagent
was removed by desalting on a PD-10 column equilibrated
with the same buffer at pH 6.0, and a thiol assay was
performed. A 3-fold molar excess of CT52 containing the 12-
N4-macrocycle group for 90Y labelling (Harrison et al., 1991)
was added to thiolated antibody or F(ab')2 and incubated for
2 h at room temperature. The number of macrocycles per
antibody was determined by measuring the number of thiol
groups remaining after addition of macrocycle. Suitable
controls revealed that the loss of thiol groups by oxidation
over time was negligible.
Antigen binding and kinetic analysis
To determine the immunoreactivity of DFM, TFM and
macrocycle conjugates compared with unmodified IgG and
F(ab')2 enzyme-linked immunosorbent assays (ELISAs) were
performed.
Microtitre plates were coated with 100 pl of CEA antigen
(perchloric acid extracted from a patient and affinity purified
in the department of Clinical Oncology) at 2 pg ml-' in
phosphate-buffered saline (PBS, Sigma) for 1 h at room
temperature, then blocked with 3% bovine serum albumin
(BSA, Sigma) in PBS overnight at 4°C. Serial doubling
dilutions (100 pl) of 10 pg ml-' DFM, TFM, F(ab')2, IgG
and macrocycle conjugates of IgG and F(ab')2 in PBS/0.05%
Tween 20, were applied to washed coated plates, for 1 h
with gentle mixing. Plates were washed four times with PBS/
0.05%Tween 20 and four times with distilled water, and
100 pl of anti-mouse peroxidase 1:1000 dilution (Amersham)
was added and incubated for 1 h with gentle mixing. After
washing, 100 pl of the substrate O-phenylenediamine
dihydrochloride (OPD, Sigma, 10 mg tablet dissolved in
40 ml of 50 mm citrate buffer, pH 5.0, with 8 pul of hydrogen
peroxide) was applied to each well. After approximately
5 min, the reaction was stopped by the addition of 4 M
hydrochloric acid. The optical density at 490 nM was
measured using a plate reader (Boots-Celltech Therapeu-
tics). This assay was repeated to ensure consistent results.
Kinetic analysis was carried out by surface plasmon
resonance using the BlAcore system (Pharmacia Biosensor)
to measure on and off rates of the above antibodies. CEA
antigen was immobilised to biosensor chips using surface
thiol chemistry or, alternatively, by aldehyde chemistry, and
the immobilised antigen density was optimised in a similar
way to that described previously (Abraham et al., 1995).
Kinetic binding parameters were calculated using BIA
evaluation software after correcting concentrations to nm
binding sites (assuming two binding sites per antibody for
IgG, F(ab')2 and DFM, three for TFM and one binding site
for F(ab'), such that antibody forms with different numbers
of binding sites could be compared.
Radiolabelling and animal studies
Labelling with 1311 was performed using the chloramine T
method. Free iodine was removed using a PD-10 column
blocked with 3% BSA and equilibrated in PBS, and
percentage incorporation of radiolabel was analysed by
thin-layer chromatography (TLC) analysis in 80% methanol.
Antibodies for 90Y labelling were first desalted into 0.1 M
MES buffer, pH 6.0, at concentrations >1 mg ml-'.
90Yttrium chloride (9OYCI3, Amersham) at 50 mCi ml-' was
added to achieve a specific activity of 2 pCi pg-' andImproved tumour targeting of multivalent Fab' fragments -_
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incubated for 20 min at room temperature. The reaction was
quenched by addition of 10 mM DTPA for 10 min at room
temperature. Incorporation was measured by TLC in a
mobile phase of 0.1 M citrate buffer, pH 5.0, and HPLC gel
filtration was used to remove any unreacted 90Y. Character-
isation of antibodies after labelling was performed to ensure
full immunoreactivity by applying a dilution of the
radiolabelled antibody to a 1 ml CEA affinity column and
measuring the percentage bound, as described previously by
Casey et al. (1995). Stability of radiolabelled antibody was
analysed by application of an aliquot of the sample to a
Sephacryl S-300 column (110 x 1 cm). Fractions (1.3 ml) were
monitored for 131I or 90Y levels. Stability at 37°C in human
serum for 24 h was also assessed.
Comparative biodistribution experiments were performed
in the nude mouse colorectal xenograft model, LS174T
(Pedley et al., 1993).
Results
Preparation ofF(ab')2, DFM and TFM
Digestion of A5B7 with bromelain enzyme routinely
produced approximately 70% fully immunoreactive F(ab')2
in 1 h. Purification of this F(ab')2 resulted in material which
was >90% pure as assessed by SDS-PAGE (Figure 1).
Cross-linking of Fab' to DFM was monitored by HPLC gel
filtration after a 2 h incubation period and resulted in yields
of approximately 40% cross-linked dimer with less than 5%
reoxidised F(ab')2. For TFM cross-linking, yields of
approximately 25% cross-linked trimer were obtained. These
yields are relatively low compared with those obtained
previously with recombinant antibody fragments, where
yields of 70% (DFM) and 60% (TFM) have been observed
(King et al., 1994). This is probably a result of using murine
A5B7 Fab', which contains three hinge cysteine residues
compared with recombinant Fab', which has a single hinge
thiol residue. Optimisation studies have shown that higher
cross-linking levels may be achieved on a larger scale at
higher antibody concentrations. DFM and TFM were
purified by HPLC gel filtration to >90% purity as
illustrated by SDS-PAGE analysis in Figure 1.
Antigen binding and kinetic analysis
Antigen binding analysis by ELISA demonstrated full
reactivity of DFM and F(ab')2-macrocycle conjugate
compared with that of native F(ab')2 (Figure 2a). DFM
also showed slightly higher binding than F(ab')2 and the
F(ab')2-macrocycle conjugate. TFM and IgG-macrocycle
retained full reactivity (Figure 2b) compared with unmodi-
fied IgG, and TFM also demonstrated a slightly higher
binding than IgG and the macrocycle conjugate. It was
important to analyse the immunoreactivity of antibody after
modification, as high levels of reducing agent or 2-
iminothiolane have been reported to cause loss of immunor-
eactivity or aggregation (Turner et al., 1994).
Kinetic analysis of antigen binding was performed using
surface plasmon resonance with a BlAcore instrument
(Pharmacia Biosensor). The amount of CEA coupled to the
sensor chip was optimised in preliminary experiments using
either PDEA surface thiol or aldehyde immobilisation. The
optimal antigen binding density for kinetic analysis was
determined at which the antibody-antigen interaction was
minimal for mass transport (768 RU for aldehyde coupling
and 2544 RU for surface thiol immobilisation of CEA).
Table I shows a comparison of association and dissociation
rate constants (k0n and k0ff) for the antibodies studied,
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Figure 1 Conjugated to macrocycle SDS -PAGE analysis (4-
20% gradient) under non-reducing conditions of purified (a)
DFM, (b) TFM, (c) F(ab')2, (d) IgG and molecular weight
markers. Gel was stained with Coomassie blue.
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Figure 2 Antigen binding analysis by ELISA of native,
conjugated and cross-linked antibodies. (a) Native F(ab')2 (A),
F(ab')2 conjugated to macrocycle (-), and DFM (-). (b) Native
IgG (A), IgG conjugated to macrocycle (-), and TFM (A). The
assay was repeated to ensure results were reproducible.
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comparing both immobilised CEA surfaces, the values being
a mean of four serial dilutations of antibody (333 nM,
167 nM, 83 nM and 42 nM). To compare forms of antibody
with different numbers of binding sites, the values have been
converted to nM binding sites for each entity. Monovalent
Fab' was included in the evaluation and showed a
considerably slower on rate (kass 3.55 x 104 mean of values
for both surfaces) and faster off rate (kdi,, 1.25 x 10-4 mean)
than the multivalent species, presumably owing to the lower
avidity of a single binding site compared with the divalent or
trivalent antibody forms. The on rates were significantly
superior for DFM (kass 1.6 x 105 mean) when compared with
mean values for both surfaces of F(ab')2 (kass 7.34 x 104), IgG
(kass 5.3 x 104) and TFM (ka.s 7.33 x 104). However, there was
little difference in off rate between the divalent and trivalent
antibodies, F(ab')2 and IgG: (kdils 0.17 x 10-4-0.47 x 10-4).
Surprisingly, the increase in avidity of TFM did not produce
higher kinetic binding, although there was a clear advantage
between mono- and divalent constructs. The dissociation rate
constants measured were close to the lower limit of detection
possible with the BlAcore system. In general, the results
obtained with the CEA immobilised via surface thiol
Table I BlAcore kinetic parameters for antibodies determined by binding to CEA immobilised by either aldehyde
coupling or surface thiol chemistry
kass (I xE4 Ms-') kdiss (I x E-4 s 1)
Aldehyde Thiol Mean Aldehyde Thiol Mean
Fab' 3.25 (±1.3) 3.84 (±0.6) 3.55 1.44 (±4.0) 1.06 (±1.4) 1.25
F(ab')2 5.17 (+1.0) 9.50 (±1.2) 7.34 0.45 (±0.04) 0.18 (±0.04) 0.32
DFM 12.5 (+2.6) 19.5 (±2.0) 16.0 0.47 (±2.5) 0.17 (±0.3) 0.32
TFM 5.46 (+1.7) 9.2 (±2.1) 7.33 0.43 (±2.1) 0.17 (±l.3) 0.30
IgG 3.64 (±1.2) 6.96 (±1.6) 5.30 0.34 (+0.2) 0.20 (±0.03 0.27
Values are corrected for number of binding sites and molecular weight and presented as association and dissociation
constants. The values are average (mean) values calculated from analysis of four concentrations of antibody, standard
deviations are in brackets. The overall mean values of both couplng methods for kass and kdiss are shown in the 'mean'
columns.
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Figure 3 Gel filtration profile of radiolabelled antibodies incubated in human serum for 24 h at 37'C. (a) DFM (-) and F(ab')2
(A) labelled with "'1I. (b) DFM (M) and F(ab')2 (A) labelled with 90Y. (c) TFM (M) and IgG (A) labelled with 131I. (d) TFM (l)
and IgG (A) labelled with 90Y. Molecular weight markers for 200 kDa and 60 kDa are marked with an arrow. C.p.m is a measure
of radioactivity in counts per minute.
6.
C)
C
E 10000
0
.^ 1,f f
,%^ ^^11 ----Improved tumour targeting of multivalent Fab' fragments
JL Casey et al M
1401
chemistry showed faster on rates and slower off rates than for
aldehyde immobilisation chemistry shown in Table I. This
probably reflects the fact that the antigen density was
significantly higher for the thiol-immobilised surface allow-
ing more rebinding events to occur during the dissociation
phase than with the alternative surface.
Radiolabelling and stability
TLC analysis of radiolabelled antibodies routinely revealed
96-99% incorporation of 131I and 90Y after purification.
Antigen binding by application of a small sample of
radiolabelled antibody to a 1 ml CEA affinity column
revealed retention of 90-96% binding. A non-CEA anti-
body was radiolabelled as a control and 2-10% total activity
bound to the column.
Antibodies after labelling and incubation at 37°C in
normal human serum remained intact and non-aggregated,
as shown in Figure 3 by S-300 gel filtration chromatography.
Biodistribution study
The biodistribution of A5B7 F(ab')2 and DFM, and also
A5B7 IgG and TFM were compared in tumour-bearing mice
over a 6 day period after radiolabelling with both 131I and
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F(ab')2 and DFM
The tissue distributions of 131- and 90Y-labelled F(ab')2 and
DFM were compared at 3, 24, 48 and 144 h time points. The
biodistribution of A5B7 F(ab')2 and DFM labelled with 1311
(Figure 4a and b) proved to be very similar, suggesting there
is no significant difference in the stability of these fragments
in vivo. Rapid clearance from the blood and normal tissues
by 24 h produced high therapeutic tumour-blood ratios
illustrated in Table 11 (38:1 F(ab')2; 26:1 DFM), which were
Table II Tumour to blood ratios of percentage injected dose at
various time intervals after injection of radiolabelled antibody
3h 24h 48h 144h
[131i]F(ab')2 0.8 38 50 71
[1 11]DFM 1.0 26 43 61
[9°1F(ab')2 0.9 23 22 5.0
[90Y]DFM 0.9 40 27 7.0
[311]IgG 0.3 2.0 4.3 23
[131i]TFM 0.5 6.0 12 44
[90Y]IgG 0.4 4.0 5.8 17
[90YTFM 0.4 15 15 14
Data are expressed as a mean of four mice.
b
Tissues
d
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Figure 4 Biodistribution of(a) [13I]F(ab')2, (b) ['31I]DFM, (c) [9rYlF(ab')2 and (d) [90Y]DFM in nude mice bearing LS174T human
tumour xenografts. Time points at 3h (first column), 24h (second column), 48h (third column) and 144h (fourth column) after i.v.
injection. Results are expressed as percentage injected dose per gram of tissue; columns are a mean of four mice and bars represent
standard deviations.
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5 Biodistribution of (a) "TI[IgG], (b) "il7FM], (c) E)Y[IgG] and (d) '0Y[TFMJ in nude-inice bearing LS174T human
tumour xenografts. Time points at 3h (irt column), 24h (second colum&l48h (third column) and 144h (fburth column) after i.Y.
injectien. Results are expressed as percentage of injected dose per grab of tissue; columns are a:-mean of four mice and bars
represent standard deviations.
retained over the 6 day period. Labelling with 90Y
dramatically altered the biodistribution (Figure 4c and d)
leading to very high accumulation in the kidney at early time
points and throughout the 6 days, producing a very different
clearance pattern to the iodinated fragments. High splenic
uptake was also observed, which accumulated over time,
especially for DFM (144 h: F(ab')2 8.5%; DFM 20%).
Despite unfavourable uptake in the kidney and spleen,
tumour uptake levels were similar to the iodinated fragments
(48 h: [0Y]DFM 10%, ['31I]DFM 6% injected dose per
gram).
IgG and TFM
The blood clearance of TFM, despite its similar size
(150 kDa), was significantly faster than IgG (P<0.02, using
the Mann-Whitney U-test non-parametric statistical analy-
sis) as illustrated in Figure 5. This produced superior
therapeutic tumour-blood ratios (Table II) at 24 h 13l1
(IgG 2:1; TFM 6:1), 90Y (IgG 4:1; TFM 15:1) and 48 h '3'I
(IgG 4:1; TFM 12:1), 90Y (IgG 5.8:1; TFM 15:1). The levels
of activity accumulated at the tumour were increased by
labelling with 90Y (Figure Sc and d); this persisted over time
and was most apparent at later time points, e.g. at 48 h: "3'I
(IgG 15% ID g-'; TFM 10% ID g-'), 9Y (IgG 25%
ID g- 1; TFM 17% ID g '). This may be caused by higher
retention of yttrium-labelled conjugates in cells compared
with iodinated conjugates that are dehalogenated. The levels
of radiolabel in the tumour for IgG and TFM were also
greater than for F(ab')2 and DFM fragments, probably as a
result of slower clearance from the circulation. However, the
lower molecular weight fragments produced high therapeutic
ratios earlier, potentially reducing toxicity and, thus,
allowing larger doses to be given. In contrast to 90Y-
labelled DFM and F(ab')2, kidney uptake levels of both
[9Y]IgG and V0Y]TFM were relatively low. However,
referring to the 144 h time point, it does appear that a
greater proportion of [9Y]TFM clears through the kidney
than [90Y]IgG (TFM 9%, IgG 3.4%), and this is also
reflected by the higher values in the liver for [9Y]IgG at this
time point (TFM 4.4%, IgG 12.8%). Slightly higher splenic
and femur uptake was observed for the [9Y]TFM compared
with flY]IgG, which may indicate non-specific uptake by
the reticuloendothelial system (RES).
Discussion
It has been widely documented that antibody fragments
injected into tumour-bearing nude mice give higher tumour
to normal tissue ratios than the parent IgG (Buchegger et al.,
1988; Pedley et al., 1993). Removal of the Fc portion may
also be beneficial owing to the removal of binding sites for Fc
receptors, thus lowering toxicity (Buchegger et al., 1992).
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However, despite these potential benefits of using F(ab')2
fragments, the lack of the Fc portion exposes the hinge
regoin, making it more susceptible to enzymatic and/or
reductive breakdown. In addition, different F(ab')2 fragments
have different in vivo stabilities. For example, in a study
comparing murine F(ab')2 from an IgG1 antibody with
chimeric F(ab')2 of human subclasses 1, 2 and 4, it was
reported that human IgG4 F(ab')2 fragments were relatively
unstable in vivo, human IgG2 the most stable and murine
IgG1 and human IgG1 F(ab')2 of intermediate stability
(Buchegger et al., 1992). Chemically cross-linked F(ab')2
fragments and trispecific F(ab')3 derivatives have been
produced through use of bis-maleimide linkers using
techniques developed by Glennie et al. (1987) and Tutt et
al. (1991). Recombinant Fab's have also been synthesised
with a single hinge thiol to facilitate cross-linking reactions
(Carter et al., 1992; King et al., 1994) and scFv molecules
with a C-terminal cysteine expressed, which allow cross-
linking (Cumber et al., 1992). In some reports, increased in
vivo stability of the cross-linked fragments has been
demonstrated (Quadri et al., 1993; King et al., 1994).
However, as F(ab')2 fragments vary in their in vivo stability
themselves, the nature of the F(ab')2 fragments must be taken
into account and direct comparisons in the same system are
necessary. In this study, we have shown that A5B7 chemically
cross-linked DFM and native F(ab')2 fragments have similar
in vitro and in vivo stability. Although higher splenic uptake
was observed for [90Y]DFM compared with [9Y]F(ab')2, there
was no significant difference in levels of activity in tissues,
including blood, kidney and tumour when labelled with either
131I or 90Y.
The major site of antibody fragment catabolism in mice is
the kidneys (Covell et al., 1986) and this was the normal
organ with the highest level of 1311 and [9rY]F(ab')2 and DFM
at early time points. Radioiodinated fragments undergo
metabolism to release low molecular weight fragments,
which are rapidly released from cells and cleared (Press et
al., 1990), whereas radiometals are retained longer owing to
cellular trapping of the chelate (Pimm et al., 1989).
Biodistribution of antibody fragments labelled with 131I and
"'In have been compared previously (Andrew et al., 1988).
For "'In-labelled F(ab')2 >60% of administered activity was
retained in the kidneys compared with <10% for
['31I]F(ab')2. This is similar to the difference we observe here
for 90Y-labelled F(ab')2 and DFM; kidney-blood ratios are
increased 3-fold at 3 h and over 100-fold at 24 h compared
with "3'1-labelled fragments.
The stability of the attachment of radiochelate to antibody
is an important determinant of therapeutic ratio, since some
labelling methods, involving derivatives of the chelating
ligand DTPA, produce relatively labile conjugates in vivo
(Harrison et al., 1991). Weak ligands will lead to both a
reduction in the amount of 90Y-conjugate in the tumour and
irradiation of the normal tissues with free 90Y, especially
proliferating tissues of the bone marrow, since 90Y is a bone-
seeking isotope (Hnatowich et al., 1983). The development of
new chelating agents, such as the macrocyclic chelating agent
DOTA (Moi et al., 1988; Cox et al., 1989), have proved to be
more stable in vivo (Hird et al., 1991; Harrison et al., 1991).
The cross-linkers used in this study contain the 12N4 DOTA
macrocycle, which allows the site-specific attachment of 90Y
and this has the added advantage that there is no loss of
antigen binding after radiolabelling. Attachment of radiolabel
in random positions, as we describe here for IgG and F(ab')2,
leads to non-homogenous preparations owing to variation in
the number of thiol groups generated, and may reduce
immunoreactivity, if residues which contribute to antigen
binding are modified.
Engineering an additional C-terminal cysteine residue on
scFv or Fab' subunits and thus providing a free thiol group,
may also be useful for site-specific radiolabelling with
technetium-99m (Verhaar et al., 1996), again allowing
retention of immunoreactivity as a result of conjugation
distant from the antigen binding sites.
The increase in valency and, therefore, avidity of divalent
fragments over monovalent fragments produced a significant
increase in kinetic association and dissociation rate-binding
parameters. However, the increase in valency from divalent
to trivalent molecules did not further increase kinetic binding.
Three Fab' arms may not all be accessible for binding at the
same time to a solid surface. Therefore, steric hindrance to
antigen sites on solid surface may explain why an increase in
association and dissociation rate was not achieved. A cell
binding assay may be more representative of binding
parameters in vivo; in a previous study improved binding of
trivalent molecules over divalent F(ab')2 was demonstrated
using this type of assay (Werlen et al., 1996).
The biodistribution of IgG and TFM in the xenograft
model showed surprisingly faster clearance for TFM
compared with whole antibody, despite having the same
molecular weight. The same phenomenom has been observed
with trivalent bis-maleimide-linked Fab' fragments described
previously (King et al., 1994; Schott et al., 1993), and may be
partially caused by the lack of the Fc portion thought to be
responsible for the long circulation time of the intact
immunoglobulin. Tumour accumulation of TFM was greater
than for the divalent fragments, and similar levels to IgG
were observed up to 24 h. The major advantage of faster
clearance leading to lower blood toxicity is that for therapy a
larger dose may be given. Again, by labelling with 90Y,
tumour retention is superior than for iodinated IgG and
TFM owing to the absence of dehalogenation and/or "31I
metabolism. Several publications (Schott et al., 1992; Sharkey
et al., 1990) have also reported this finding, which could also
explain the higher percentage injected dose of the 90Y-labelled
antibodies in normal tissues, such as kidney spleen and liver.
The splenic uptake of 90Y-labelled DFM and TFM was
notably higher than the F(ab')2 and IgG. This indicates that
there may be some RES uptake ofthe cross-linked fragments.
This will require further investigation and dosimetry
evaluation with higher doses of radioconjugate.
In contrast to the divalent fragments, kidney accumulation
was greatly reduced. This is presumably mainly due to the
increase in molecular weight, although the slight increase in
kidney levels of TFM compared with IgG suggest that there
may be other factors, such as shape and charge, which also
influence the filtration process (Sumpio and Hayslett, 1985).
Catabolism of TFM to form F(ab')2 or Fab' fragments could
also occur, which may also contribute to increased kidney
uptake. However, there is no evidence to suggest reabsorp-
tion of fragmented TFM or DFM, or breakdown occurring
in the serum, by HPLC analysis of serum from mice injected
with labelled DFM and TFM (unpublished finding).
In the present study, DFM showed faster blood clearance
than TFM and IgG and similar biodistribution to F(ab')2 in
the xenograft model. High kidney accumulation of both
[9'Y]DFM and [9Y]F(ab')2 and increased splenic uptake of
[9Y]DFM is clearly unacceptable for RIT. However, this
high kidney and splenic uptake was not seen on labelling with
1311 DFM has a faster kon rate than F(ab')2 and all the other
antibody forms, which may be a consequence ofthe increased
spacing or flexibility of the chemical cross-linker. Therefore,
although the biodistribution data demonstrate equivalent
tumour uptake levels, we conclude that A5B7 DFM, owing
-to its faster kon rate, may be more suitable than F(ab')2 when
radiolabelled with 131I for RIT.
TFM clears faster from the blood than IgG and produces
higher tumour uptake and lower kidney accumulation than
DFM and F(ab')2 radiolabelled with 90Y. Although there is a
slight elevation in splenic uptake, this combination avoids
long blood circulation time, which is dose limiting, and
spares the kidneys from damage by radiation accumulation.
Therefore, from these results we conclude that 90Y-labelled
A5B7 TFM would be the most suitable antibody species for
RIT.
The superior pharmacokinetics of murine versions of
DFM and TFM compared with the parent IgG and F(ab')2
in vivo, coupled with the ability to re-treat patients by usingx-"- Improved tumour targeting of multivalent Fab' fragments
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humanised forms, should provide improved clinical therapy
in the future. A humanised Fab' version of A5B7 has been
constructed (Adair et al., 1992) and preliminary data
involving hDFM and hTFM are promising.
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